Our Framework
The Problem Isn't a Lack of Innovation.
Across universities, research labs, and technology transfer offices, promising women's health innovations already exist. Diagnostics, devices, therapeutics, and platform technologies are being developed every day.
Yet many never reach the women who need them most.
Too often, products are not adapted for African healthcare environments, validated in relevant populations, or supported by the pathways needed for real-world adoption.
Misala exists to bridge that gap.
The Challenge
Translating Innovation Into Impact.
Misala identifies promising women's health innovations and helps move them from research to real-world use.
We license market-facing technologies globally and guide them through the stages required for successful adoption in African markets, including productisation, contextual adaptation, clinical validation, regulatory alignment, manufacturing, and distribution.
Our focus is not invention for invention's sake. It is the disciplined translation of credible science into solutions that women and clinicians can access, trust, and use.
To do this, we follow a repeatable framework designed to support women at every stage of care.
How We Work
A staged model that begins with lower-regulatory-burden products, builds trust and data, and expands into diagnostics and therapeutics over time.
Capital-efficient expansion
Local validation, regulatory adaptation, product design, and distribution built for African healthcare realities.
Last-mile
execution
Women's health categories where clinical burden, public health priorities, and market demand converge.
Policy-aligned markets
On-patent technologies
Protected innovations with scientific credibility and commercial potential.
The Four Pillars
Our Focus
This is a repeatable model designed to close the gap between the patient, the clinician, the tools, and the data needed to improve care.
We build toward licensed, clinically validated therapeutics adapted for African populations, workflows, and regulatory pathways. Treat is the layer where data, diagnosis, and product development converge into more definitive options for conditions that have been underserved for too long.
TREAT
We develop or license low-infrastructure diagnostic tools that give women and clinicians clearer answers, faster. Detect is where uncertainty becomes clinical clarity through tools designed for real healthcare environments, not only ideal laboratory settings.
DETECT
We produce science-backed wellness interventions that combine modern formulation standards with African medicinal knowledge, including carefully selected indigenous botanicals. This layer is built with empathy and rigor: to support women now, build trust, and create an accessible first step into better care.
RESET
A repeatable model designed to move women and clinicians from uncertainty to clarity, and from fragmented care to integrated solutions.
Reset. Detect. Treat.
Our Framework
In Her Reset Era
A 7-day oral sachet designed as a provider-led vaginal ecosystem reset protocol. Supporting vaginal microbiome health from the inside out, without shame.
AI-supported BV Diagnostics
An AI-supported diagnostic tool for BV, built on automated microscopy and trained on African women's vaginal health data. Designed for real clinical environments, not just reference labs.
Future Pipeline
A pipeline of licensed, clinically validated therapeutics informed by local clinical data and adapted for the African context. Built on the foundation the Reset and Detect layers create.
Starting where the gap is most pressing and closeable now.
We begin with vaginal dysbiosis — a condition affecting millions of women globally, chronically underdiagnosed, and historically undertreated.
Our first product loop spans Reset, Detect, and Treat — starting with In Her Reset Era.
Our First Loop: Vaginal Dysbiosis
Non-hormonal support products, symptom-stratification tools, and future therapeutics adapted for African women and health systems.
Menopause: Developing
Earlier detection, better symptom management, and access to therapeutics that move beyond surgical crisis as the default intervention.
Uterine Fibroids: Future
Microbiome support, AI-assisted BV diagnostics, and a future pipeline of targeted therapeutics. Our first and most developed loop.
Vaginal Dysbiosis: Active
Our Pipeline
Misala is building a repeatable model, and we are already looking ahead.